Jacobs Levy Equity Management, Inc Adicet Bio, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	BUY	$1.37 - $3.4 $12,928 - $32,085	9,437 Added 2.91%	333,593 $457,000
Q2 2023 Aug 14, 2023	BUY	$2.13 - $7.13 $100,947 - $337,912	47,393 Added 17.12%	324,156 $787,000
Q1 2023 May 15, 2023	BUY	$5.52 - $9.23 $1.14 Million - $1.91 Million	207,381 Added 298.9%	276,763 $1.59 Million
Q4 2022 Feb 14, 2023	BUY	$7.72 - $21.27 $535,629 - $1.48 Million	69,382 New	69,382 $620,000
Q1 2022 May 16, 2022	SELL	$11.53 - $19.97 $317,040 - $549,115	-27,497 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.18 - $21.4 $279,919 - $588,435	27,497 New	27,497 $327,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $36M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.